Veronica Harsh1, Anita H Clayton2. 1. Department of Psychiatry & Neurobehavioral Sciences, University of Virginia, 2955 Ivy Rd, Suite 210, Charlottesville, VA, 22903, USA. vlh3p@hscmail.mcc.virginia.edu. 2. Department of Psychiatry & Neurobehavioral Sciences, University of Virginia, 2955 Ivy Rd, Suite 210, Charlottesville, VA, 22903, USA.
Abstract
PURPOSE OF REVIEW: Sex differences in the treatment of sexual dysfunction are partly due to neurobiological differences, as well as, the central and peripheral physiological effects of hormones and neurotransmitter actions on reproductive systems in men and women. Differences in epidemiology of complaints and diagnostic considerations, variance in medical comorbidities, and interference from related medications also contribute to the need for different strategies for treatments of sexual dysfunction according to gender. RECENT FINDINGS: Flibanserin and ospemifene are new medication treatment options that may help some women with symptoms of sexual dysfunction. Various therapies are available to address sexual dysfunction and sex differences are relevant to consider, in terms of diagnosis, effectiveness of treatments, and side effect profiles that may help determine indication, safety, and outcomes for specific treatments.
PURPOSE OF REVIEW: Sex differences in the treatment of sexual dysfunction are partly due to neurobiological differences, as well as, the central and peripheral physiological effects of hormones and neurotransmitter actions on reproductive systems in men and women. Differences in epidemiology of complaints and diagnostic considerations, variance in medical comorbidities, and interference from related medications also contribute to the need for different strategies for treatments of sexual dysfunction according to gender. RECENT FINDINGS:Flibanserin and ospemifene are new medication treatment options that may help some women with symptoms of sexual dysfunction. Various therapies are available to address sexual dysfunction and sex differences are relevant to consider, in terms of diagnosis, effectiveness of treatments, and side effect profiles that may help determine indication, safety, and outcomes for specific treatments.
Entities:
Keywords:
Neurobiology; Pharmacotherapy; Sex differences; Sexual dysfunction; Treatment options
Authors: Catherine B Johannes; Anita H Clayton; Dawn M Odom; Raymond C Rosen; Patricia A Russo; Jan L Shifren; Brigitta U Monz Journal: J Clin Psychiatry Date: 2009-12 Impact factor: 4.384
Authors: Paula L Jacobsen; Atul R Mahableshwarkar; William A Palo; Yinzhong Chen; Marianne Dragheim; Anita H Clayton Journal: CNS Spectr Date: 2015-11-17 Impact factor: 3.790
Authors: Paula L Jacobsen; Atul R Mahableshwarkar; Yinzhong Chen; Lambros Chrones; Anita H Clayton Journal: J Sex Med Date: 2015-08-31 Impact factor: 3.802
Authors: Tina Kiguradze; William H Temps; Steven M Belknap; Paul R Yarnold; John Cashy; Robert E Brannigan; Beatrice Nardone; Giuseppe Micali; Dennis Paul West Journal: PeerJ Date: 2017-03-09 Impact factor: 2.984
Authors: Paolo Cassano; Christina Dording; Garrett Thomas; Simmie Foster; Albert Yeung; Mai Uchida; Michael R Hamblin; Eric Bui; Maurizio Fava; David Mischoulon; Dan V Iosifescu Journal: Lasers Surg Med Date: 2018-09-17 Impact factor: 4.025